Cesca Therapeutics is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. We focus in three target markets to serve patients, physicians and partners:
•Cellular Therapeutics
•Medical/Diagnostic Device Development and Commercialization
•Cell Manufacturing and Banking
Therapies: Cesca’s lead therapeutic technology platform, SurgWerks® (an intraoperative rapid system for harvesting, selection/purification, testing, and delivering a therapeutic dose of autologous bone marrow derived or peripheral blood derived cells and proteins), is currently in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries.
Medical and Diagnostic Devices:
Cesca designs, manufactures and sells advanced devices created specifically for the regenerative medicine bioprocessing market. This market includes biologic collection, transport, processing/washing, characterization/analysis, and cryopreservation. We view the regenerative medicine bioprocessing market as essential to the success of clinical trials through the control of quality of small and large scale cellular manufacturing in three distinct markets (below). Cesca provides an indication-specific device/protocol program called “Cell Werks™” for select applications in the following three markets:
•Umbilical Cord Blood Banking
•Bone Marrow Transplantation
•RegenMed Bio-Process (Clinical/Commercialization Stage Regen Med Companies)

Cesca Therapeutics was founded in 1986 and is headquartered in Rancho Cordova, US

Cesca Therapeutics has offices in Rancho Cordova and Gurgaon

Gurgaon, IN (HQ)

857 Udyog Vihar Phase V

Rancho Cordova, US (HQ)

2711 Citrus Rd

Cesca Therapeutics's revenue was reported to be $3.3 m in Q3, 2017

USD

## Revenue (Q3, 2017) | 3.3 m |

## Gross profit (Q3, 2017) | 1.4 m |

## Gross profit margin (Q3, 2017), % | 42% |

## Net income (Q3, 2017) | (2.1 m) |

## EBIT (Q3, 2017) | (2.1 m) |

## Market capitalization (21-Jul-2017) | 35.2 m |

## Cash (31-Mar-2017) | 3.8 m |

Cesca Therapeutics's current market capitalization is $35.2 m.

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Revenue | 16 m | 16 m | 11.9 m |

## Revenue growth, % | 0% | (26%) | |

## Cost of goods sold | 10.1 m | 11.3 m | 9.2 m |

## Gross profit | 5.9 m | 4.7 m | 2.7 m |

## Gross profit Margin, % | 37% | 30% | 23% |

## Sales and marketing expense | 3 m | 3 m | 2.1 m |

## R&D expense | 3.5 m | 5.9 m | 3.2 m |

## General and administrative expense | 8.5 m | 10.7 m | 8.2 m |

## Operating expense total | 14.9 m | 19.6 m | 13.6 m |

## EBIT | (9 m) | (14.9 m) | (10.9 m) |

## EBIT margin, % | (57%) | (93%) | (91%) |

## Interest expense | (1.9 m) | ||

## Interest income | 6 k | ||

## Net Income | (8.6 m) | (14.9 m) | (18.6 m) |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 3.7 m | 4.6 m | 4 m | 2.8 m | 3.3 m | 2.8 m | 3.8 m | 4 m | 3.3 m |

## Cost of goods sold | 2.5 m | 3.1 m | 2.9 m | 2.5 m | 2.3 m | 2.4 m | 2.4 m | 2.5 m | 1.9 m |

## Gross profit | 1.2 m | 1.5 m | 1.1 m | 367 k | 1 m | 408 k | 1.4 m | 1.6 m | 1.4 m |

## Gross profit Margin, % | 32% | 33% | 28% | 13% | 31% | 14% | 37% | 39% | 42% |

## Sales and marketing expense | 808 k | 720 k | 787 k | 632 k | 527 k | 537 k | 481 k | 294 k | 335 k |

## R&D expense | 1.5 m | 1.5 m | 1.7 m | 1.1 m | 646 k | 708 k | 670 k | 694 k | 567 k |

## General and administrative expense | 2.2 m | 3.6 m | 3.5 m | 2.6 m | 1.8 m | 1.9 m | 2.2 m | 4.1 m | 2.6 m |

## Operating expense total | 4.5 m | 5.9 m | 6 m | 4.3 m | 3 m | 3.1 m | 3.3 m | 5.1 m | 3.5 m |

## EBIT | (3.3 m) | (4.4 m) | (4.8 m) | (3.9 m) | (2 m) | (2.7 m) | (1.9 m) | (3.6 m) | (2.1 m) |

## EBIT margin, % | (90%) | (94%) | (120%) | (139%) | (60%) | (97%) | (52%) | (89%) | (65%) |

## Interest expense | (10.5 m) | (2 k) | (19 k) | ||||||

## Interest income | (9 k) | (18 k) | |||||||

## Net Income | (3.3 m) | (4.4 m) | (4.8 m) | (3.4 m) | (624 k) | (10.9 m) | (22.4 m) | (3.4 m) | (2.1 m) |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 14.8 m | 3.4 m | 5.8 m |

## Accounts Receivable | 6.2 k | ||

## Inventories | 524 m | ||

## Current Assets | 25.3 m | 13.3 m | 12.8 m |

## Goodwill | 13.3 m | 13.2 m | 13.2 m |

## Total Assets | 62.9 m | 50.8 m | 49.9 m |

## Accounts Payable | 184.9 k | 2.6 m | |

## Current Liabilities | 6.4 m | 7.9 m | 5.5 m |

## Total Liabilities | 17.6 m | ||

## Retained Earnings | (122.8 m) | (137.7 m) | (156.3 m) |

## Total Equity | 48.7 m | 34.9 m | 32.3 m |

## Financial Leverage | 1.3 x | 1.5 x | 1.5 x |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 10.7 m | 8.4 m | 4.8 m | 6.6 m | 2.9 m | 7.2 m | 5.6 m | 4.9 m | 3.8 m |

## Inventories | 5.9 m | 5.2 m | 5 m | 4 m | 4 m | 3.5 m | |||

## Current Assets | 21.5 m | 18.4 m | 15.7 m | 14.3 m | 10.7 m | 15.1 m | 12.2 m | 10.9 m | 10.6 m |

## Goodwill | 13.3 m | 13.2 m | 13.2 m | 13.2 m | 13.2 m | 13.2 m | 13.2 m | 13.2 m | 13.2 m |

## Total Assets | 59.2 m | 56 m | 53.4 m | 51.9 m | 48.2 m | 52.4 m | 49.2 m | 47.9 m | 46.8 m |

## Accounts Payable | 3 m | 3.2 m | 4.7 m | 5.7 m | 4.4 m | 3.3 m | 1.8 m | 2.1 m | 1.9 m |

## Current Liabilities | 5.7 m | 6.6 m | 8.4 m | 8.9 m | 7.4 m | 5.9 m | 3.9 m | 5.4 m | 4.7 m |

## Retained Earnings | (126.1 m) | (130.5 m) | (135.3 m) | (141.1 m) | (141.7 m) | (152.6 m) | (178.7 m) | (182.1 m) | (184.2 m) |

## Total Equity | 45.6 m | 41.6 m | 37 m | 32.3 m | 32.2 m | 35.8 m | 36.3 m | 33.7 m | 31.8 m |

## Financial Leverage | 1.3 x | 1.3 x | 1.4 x | 1.6 x | 1.5 x | 1.5 x | 1.4 x | 1.4 x | 1.5 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | (8.6 m) | (14.9 m) | (18.6 m) |

## Depreciation and Amortization | 993 k | 1.4 m | 1.2 m |

## Accounts Receivable | (2.1 k) | (487) | 2 m |

## Inventories | 6.4 k | 42.1 k | |

## Accounts Payable | (2.4 m) | ||

## Cash From Operating Activities | (7.8 m) | ||

## Capital Expenditures | (402 k) | (587 k) | (710 k) |

## Cash From Investing Activities | (51 k) | (587 k) | (710 k) |

## Cash From Financing Activities | 15.8 m | (189 k) | 12.8 m |

## Free Cash Flow | (8.2 m) |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (3.3 m) | (4.4 m) | (4.8 m) | (3.4 m) | (624 k) | (10.9 m) | (22.4 m) | (3.4 m) | (2.1 m) |

## Inventories | 5.9 m | 5.2 m | 5 m | 4 m | 4 m | 3.5 m | |||

## Accounts Payable | 3 m | 3.2 m | 4.7 m | 5.7 m | 4.4 m | 3.3 m | 1.8 m | 2.1 m | 1.9 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 34.2 k |

## Financial Leverage | 1.5 x |